key: cord-0893504-4sfg9iwd
authors: Lecarpentier, Yves; Vallée, Alexandre
title: The key role of the level of ACE2 gene expression in SARS-CoV-2 infection
date: 2021-06-11
journal: Aging (Albany NY)
DOI: 10.18632/aging.203181
sha: 8b78768be6631683d651f462c100c453b4a8384d
doc_id: 893504
cord_uid: 4sfg9iwd

SARS-CoV-2 more readily affects the elderly, especially as they present co-morbidities. In the COVID-19 pathogeny, ACE2 appears to be the key cell receptor for SARS-CoV-2 to infect humans. The level of ACE2 gene expression influences the susceptibility of contracting SARS-CoV-2. In circumstances in which the ACE2 level is low, the incidence of Covid-19 seems to be fewer. Two clinical patterns illustrate this observation, i. e., in infants and in Alzheimer's disease (AD). Very young children and AD patients get little COVID-19, in part probably due to decreased expression of ACE2. The determination of the nasal level of ACE2 gene expression could provide a useful scale to predict the susceptibility to contract the SARS-CoV-2 infection.

The pandemic coronavirus disease-2019 (COVID- 19) affect millions of individuals and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been shown to be responsible for it. The primary target for entry into host cells has been identified to be the multifunctional protein angiotensin converting enzymerelated carboxypeptidase (ACE2) discovered simultaneously by Donoghue et al. and Tipnis et al. [1, 2] . SARS-CoV-2 more readily affects the elderly [3] , especially as they present co-morbidities such as type 2 diabetes, hypertension, chronic obstructive pulmonary disease and cancers [4, 5] . Mortality due to Covid-19 is highly associated with elderly [3] . In COVID patients, the ACE2 protein level significantly increases in both alveolar tissue and bronchial epithelium of diabetic patients [6] and this can partly explain the high rate of infectivity of SARS-CoV-2 in these patients. In hypertensive and diabetic patients treated with ACE inhibitors or angiotensin II type-I receptor blockers (ARBs), an upregulation of ACE2 has been reported [7] . This could facilitate the SARS-CoV-2 infection and increase the risk of developing severe and fatal SARS-CoV-2 infection.

In the COVID-19 pathogeny, ACE2 appears to be the key cell receptor for SARS-CoV-2 to infect humans [8] [9] [10] [11] [12] . The human coronavirus SARS-CoV-2 binds with its target cells through ACE2, which is largely expressed, particularly in lung, intestine, kidney and blood vessel cells [7] . Thus, SARS-CoV-2 uses its spike protein S1 to enter cells by interacting with the ACE2 receptor on the cell surface membrane. Thus, SARS-CoV-2 acts directly on cells through the ACE2 receptor leading to downregulate the ACE2 expression by binding with the spike (S) viral protein [8, 12, 13] . This decreases the degradation of angiotensin II (Ang-II) into angiotensin1-7 (Ang-(1-7) [14] . ACE2 converts Ang-II to Ang-(1-7) and prevents the effects of the ACE1/angiotensin II axis. Ang-II induces strong vasoconstriction, inflammatory effects, and profibrotic effects, while Ang-(1-7) exhibits antiproliferative, antiapoptotic, and mild vasodilation and protects against various cardiovascular diseases [15] . The question arises whether the level of ACE2 gene expression influences the susceptibility of contracting SARS-CoV-2. Since SARS-CoV-2 infects the elderly especially as they present co-morbidities with high levels of ACE2 [2] , it can be hypothesized that in circumstances in which the ACE2 level is low, the AGING incidence of COVID-19 might be fewer. Two clinical patterns make it possible to illustrate this point, i. e., ACE2 level expression in very young infants and in Alzheimer's disease (AD).

In infants compared to adults, numerous studies have highlighted the low rates of SARS-CoV-2 infection [16] . Children account for about 2% of cases of Covid-19 [17] . Children have lower risk of SARS-CoV-2 infection and mortality [18] . Moreover, in the nasal epithelium of the upper airway, a lower ACE2 expression has been recently reported in infants [19] . Importantly, there is an age-dependent ACE2 gene expression in the nasal epithelium which represents the first contact between SARS-CoV-2 and the human body. ACE2 gene expression is lowest in younger infants (aged <10 years), and progressively increases with age in older infants (aged 10-17 years), young adults (aged 18-24 years) and adults (aged > 25 years). The positive and quasi linear relationship between ACE2 gene expression and age appears to be independent of sex and asthma. The lower nasal ACE2 gene expression in children compared to adults may partly explain why SARS-CoV-2 is less prevalent in infants and why they have lower risk of mortality [20] .

A clinical study has reported that in AD patients with SARS-CoV-2 pneumonia, the duration from hospitalization to discharge has been shown to be shorter and AD-SARS-CoV-2 patients are less likely to report fatigue and present a better prognosis than non-AD SARS-CoV-2 patients [21] . AD patients have a higher clustering onset than non-AD patients. The duration from the onset of symptoms to hospitalization are shorter in AD patients. The role of ACE2 activity in the AD pathophysiology has been reported [22, 23] .

In the central nervous system, ACE2 also presents a non-enzymatic function, by hydrolyzing the key peptide amyloid-β which plays a key role in the AD pathogenesis. Substrates for ACE2 include amyloid-β peptides. ACE2 can efficiently hydrolyze Aβ43 to Aβ42, which is further degraded to the less toxic Aβ40 by ACE [24] . Aβ43 represents a highly amyloidogenic Aβ peptide that induces plaque formation in the brain. Importantly, ACE2 activity is significantly reduced in the frontal cortex and hypothalamus of OXYS AD rats and in the mid-frontal cortex of AD patients, and this is associated with increased parenchymal Aβ and Tau levels [25, 26] . ACE2 is reduced in AD in association with increased amyloid-β and Tau [25] . Conversely, ACE2 overexpression reduces the brain Aβ-induced disease or ACE2 activation by diminazene aceturate improves the cognitive performance [27, 28] and ameliorates Aβ-induced inflammatory processes [29, 30] . In ACE2 knockout mice, the cognitive functions decrease [31] .

Ang-(1-7) reduces the AD-related disease. Angiotensin-(1-7) administration attenuates AD disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation [32] . Intracerebroventricular infusion of Angiotensin-(1-7) ameliorates cognitive impairment and memory Dysfunction in a AD mouse model [33] . Ang-(1-7) level is decreased in the plasma of AD patients [34] and in brain tissue of AD mice. Ang-(1-7) is reduced and there is an inverse relationship between Ang-(1-7) and Tau hyper-phosphorylation in AD animal models [35] which induces neurofibrillary tangles, a histopathological hallmark of AD. Moreover, AVE0991, a nonpeptide analogue of Ang-(1-7) attenuates aging-related neuroinflammation [36] . A novel Angiotensin-(1-7) glycosylated Mas receptor agonist has been used for treatment of inflammationrelated memory dysfunction cognitive impairment in a mouse model [37] . In rat neurons, side-chain-oxidized oxysterols upregulate the ACE2 expression level and Mas receptor [38] . The Ang-(1-7) / Mas receptor signaling is deceased in AD patients [23] . Ang (1-7) levels have been found to be reduced in cerebral cortex and hippocampus in an AD sporadic mouse model associated with hyperphosphorylation of Tau [35] . Furthermore, in AD patients, the plasma concentration of Ang-(1-7) is significantly reduced, suggesting that plasma Ang-(1-7) may represent a potential biomarker for AD diagnosis [34] . As the ACE2 gene expression is reduced in AD patients [25] , the decrease in ACE2 expression level could protect against SARS-CoV-2 infection in AD and might partly account for the resilience observed in AD-SARS-CoV-2 patients.

Taken together, these studies show that the ACE2 expression level is decreased in AD [39] .

In conclusion, very young children get little COVID-19, probably partly due to the decreased expression of ACE2 at the nasal level. AD patients without associated co-morbidities seem relatively protected against Sars-CoV-2 partly due to the decreased expression of ACE2 at the cerebral level. The determination of the nasal level of ACE2 gene expression could provide a useful scale to predict the susceptibility to contract the SARS-CoV-2 infection.

The authors declare that they have no conflicts of interest.

& This corresponding author has a verified history of publications using the personal email address for correspondence.

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

A human homolog of angiotensinconverting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Angiotensinconverting enzyme 2 (ACE2) expression increases with age in patients requiring mechanical ventilation

Use of renin-angiotensinaldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Expression of ACE2, the SARS-CoV-2 Receptor, in Lung Tissue of Patients With Type 2 Diabetes

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Interplay of Opposing Effects of the WNT/β-Catenin Pathway and PPARγ and Implications for SARS-CoV2 Treatment

The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

ACE2: from vasopeptidase to SARS virus receptor. Trends www.aging-us.com 14555

The ACE2/Angiotensin

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Nasal ACE2 Levels and COVID-19 in Children

Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults

Epidemiology of COVID-19 Among Children in China

Resilience of Alzheimer's Disease to COVID-19

The depressor axis of the renin-angiotensin system and brain disorders: a translational approach

Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease

Conversion of Aβ43 to Aβ40 by the successive action of angiotensinconverting enzyme 2 and angiotensin-converting enzyme

Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-β and tau pathology

Modulation of the expression of genes related to the system of amyloid-beta metabolism in the brain as a novel mechanism of ceftriaxone neuroprotective properties

ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease

Mas Axis by Diminazene Ameliorates Alzheimer's Disease in the D-Galactose-Ovariectomized Rat Model: Role of PI3K/Akt Pathway

ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice

Overexpression of Angiotensin-Converting Enzyme 2 Ameliorates Amyloid β-Induced Inflammatory Response in Human Primary Retinal Pigment Epithelium

Deficiency of angiotensin-converting enzyme 2 causes deterioration of cognitive function

Angiotensin-(1-7) administration attenuates Alzheimer's disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation

-7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer's Disease

-7) is a Potential Biomarker for Alzheimer's Disease

Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer's Disease

AVE0991, a nonpeptide analogue of Ang-(1-7), attenuates agingrelated neuroinflammation

A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction

Cedazo-Mínguez A. side-chain-oxidized oxysterols upregulate ACE2 and Mas receptor in rat primary neurons

Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury